Compare EE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EE | EVO |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 934.1M |
| IPO Year | 2022 | N/A |
| Metric | EE | EVO |
|---|---|---|
| Price | $33.23 | $3.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $39.20 | $7.00 |
| AVG Volume (30 Days) | ★ 356.5K | 111.3K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $1,228,263,000.00 | N/A |
| Revenue This Year | $23.59 | $1.37 |
| Revenue Next Year | $24.37 | $10.05 |
| P/E Ratio | $26.40 | ★ N/A |
| Revenue Growth | ★ 44.26 | N/A |
| 52 Week Low | $21.29 | $2.31 |
| 52 Week High | $43.18 | $4.80 |
| Indicator | EE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 58.88 |
| Support Level | $32.35 | $2.87 |
| Resistance Level | $35.73 | $3.78 |
| Average True Range (ATR) | 1.34 | 0.11 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 29.29 | 66.95 |
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.